+

WO2006130745A1 - Conjugues macromoleculaires de la proteine morphogenetique osseuse 7 - Google Patents

Conjugues macromoleculaires de la proteine morphogenetique osseuse 7 Download PDF

Info

Publication number
WO2006130745A1
WO2006130745A1 PCT/US2006/021215 US2006021215W WO2006130745A1 WO 2006130745 A1 WO2006130745 A1 WO 2006130745A1 US 2006021215 W US2006021215 W US 2006021215W WO 2006130745 A1 WO2006130745 A1 WO 2006130745A1
Authority
WO
WIPO (PCT)
Prior art keywords
bmp
bone morphogenetic
morphogenetic protein
composition according
protein
Prior art date
Application number
PCT/US2006/021215
Other languages
English (en)
Inventor
Samuel Zalipsky
Francis X. Farrell
Beth Hill
Radwan Kiwan
Original Assignee
Alza Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corporation filed Critical Alza Corporation
Priority to JP2008514832A priority Critical patent/JP2008542388A/ja
Priority to EP06760616A priority patent/EP1893238A1/fr
Publication of WO2006130745A1 publication Critical patent/WO2006130745A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Definitions

  • the subject matter described herein relates to a modification of bone morphogenetic proteins. More specifically, subject relates to a modified bone morphogenetic protein modified with one or more hydrophilic polymer chains.
  • TGF-beta transforming growth factor-beta
  • BMP-7 Isolated bone morphogenetic protein 7
  • BMP-7 has been shown to induce cartilage and/or bone formation when administered to humans. It is also believed to assist in wound healing and tissue repair. More recently, BMP-7 has been proposed for use in treating diseased or damaged kidneys. Exogenously supplied BMP-7 protein tends to increase the rate of renal filtration, and in diseased kidney it tends to decrease in the rate of deterioration of the kidney function (Morrissey, J. et al., J. Am Soc Nephrol., 13:S14-S21 (2002); Simon, M. Am. J. Physiol Renal Physiol., F382-F389 (1999); Zeisburg, M. et al., J.
  • BMP-7 as a therapeutic protein suffers from a number of problems.
  • the propensity of the protein to form bone at the site of injection is problematic for therapies when bone formation is not desired, as in wound healing, tissue repair, and treatment of kidney dysfunction.
  • Another difficulty is its low solubility at neutral pH.
  • BMP-7 is soluble at pH ⁇ 6.0, injections of acidic solutions are more painful and irritating to the patient than are solutions that are essentially at physiological pH.
  • BMP-7 also suffers from the problem common to many proteins when administered via injection of a relatively fast in vivo clearance rate (Ty 2 « 1.5 h in rats).
  • a modified BMP protein and in particular, a modified BMP-7 protein, that addresses these difficulties in using BMP proteins as therapeutic agents is desired.
  • composition comprised of an isolated bone morphogenetic protein covalently attached to a hydrophilic polymer.
  • the bone morphogenetic protein is bone morphogenetic protein-7.
  • the bone morphogenetic protein-7 is human recombinant bone morphogenetic protein-7.
  • An exemplary amino acid sequence of human bone morphogenetic protein-7 is given herein as SEQ ID NO:1.
  • the hydrophilic polymer attached to the protein is poly(ethylene glycol).
  • the poly(ethylene glycol) can be of any molecular weight, and in one embodiment has a molecular weight of between about 10-50 kDaltons.
  • the bone morphogenetic protein is conjugated via two or more amino acid residues to said hydrophilic polymer.
  • composition described above in another aspect, a pharmaceutical preparation comprised of the composition described above and a pharmaceutically-acceptable vehicle is described.
  • a method of treatment wherein the pharmaceutical preparation or the composition described above is administered via injection to a subject.
  • a composition of conjugates comprised of bone morphogenetic protein-7 modified with a hydrophilic polymer is described, the composition of conjugates prepared according to the process of reacting bone morphogenetic protein-7 with a functionalized hydrophilic polymer in the presence of an activating agent.
  • activation agents include of N- hydroxysuccinimide (HOSu), 1-hydroxybenzotriazole (HOBt), and hydroxyl-7- azabenzotriazole (HOAt).
  • the functionalized hydrophilic polymer is an activated derivative of poly(ethylene glycol).
  • An exemplary activated derivative of poly(ethylene glycol) is nitrophenyl carbonate derivatized methoxy-polyethylene glycol.
  • composition formed by the process described herein provides a heterogenous composition of conjugates having a ratio of PEG:bone morphogenetic protein-7 of 1 :1 , 2:1 and 3:1. In one embodiment, the composition comprises more than about 50% of conjugates having a 1 :1 ratio of PEG:bone morphogenetic protein-7.
  • Fig. 1 shows a synthetic reaction scheme for preparation of a poly(ethylene glycol)-BMP-7 conjugate referred to herein as "PEG30k-BMP-7", where BMP-7 is covalently attached to nitrophenyl carbonate derivatized methoxy-polyethylene glycol (mPEG-NPC) in presence of ⁇ /-hydroxysuccinimide (HOSu);
  • Figs. 2A-2B are HPLC-SEC traces of the PEG30k-BMP-7 conjugate prior to purification, prepared according to the reaction shown in Fig. 1 (Fig. 2A) and of mature BMP-7 (Fig. 2B);
  • Fig. 3 shows the HPLC-SEC trace of the purified PEG30k-BMP-7 conjugate prepared according to the reaction shown in Fig. 1 ;
  • Figs. 4A-4B are SDS-PAGE gels of the purified PEG30k-BMP-7 conjugate prepared according to the reaction shown in Fig. 1 stained with Coomassie blue for protein detection (Fig. 4A) and iodine for PEG detection (Fig. 4B). Lanes: 1 , mature BMP-7; 2, PEG30k-BMP-7 conjugate; 3, fraction containing pure 1 :1 PEG30k-BMP-7; 4, protein molecular weight standards on the left gel and PEG standards on the right; 5, 6, and 7 contain the same samples as in 1 , 2, and 3 after thiolysis;
  • Fig. 5 shows another synthetic reaction scheme for preparation of a poly(ethylene glycol)-BMP-7 conjugate referred to herein as "PEG20k-Hz-BMP-7", where the glyco portion of BMP-7 is oxidized and then reacted with mPEG- hydrazide;
  • Figs. 6A-6C are HPLC-SEC traces for the mPEG20k-Hz-BMP-7 conjugate
  • FIG. 6A shows the HPLC-SEC trace of the purified PEG20k-Hz-BMP-7 conjugate prepared according to the reaction shown in Fig. 5;
  • Fig. 8 is a plot showing induction of alkaline phosphatase in rat osteoblastic
  • ROS ROS cells in vitro upon exposure to various concentrations, in ng/mL, of the
  • Figs. 9A-9C are plots of interleukin-6 (IL-6) concentration, in pg/mL, as a function of BMP-7 concentration, in ng/mL, when human kidney cells in vitro are exposed to mature BMP-7 (squares), PEG20k-Hz-BMP-7 (inverted triangles) or
  • PEG30k-BMP-7 (triangles), the concentration of BMP-7 ranging from 50 ng/mL to
  • Figs. 10A-10C are plots of interleukin-8 (IL-8) concentration, in pg/mL, as a function of BMP-7 concentration, in ng/mL, when human kidney cells in vitro are exposed to mature BMP-7 (squares, control), PEG20k-Hz-BMP-7 (inverted triangles) or PEG30k-BMP-7 (triangles), the concentration of BMP-7 ranging from
  • Fig. 11 is a graph of BMP-7 serum concentration, in ng/mL, as a function of time, in hours, after intravenous injection of mature BMP-7 (triangles), PEG30k-
  • BMP-7 inverted triangles
  • saline vehicle squares
  • Figs. 12A-12B are bar graphs showing the control normalized level of alpha-smooth muscle actin (Fig. 12A) and collagen alpha1(l) (Fig. 12B) in mice after unilateral ureteral obstruction and treatment with mature BMP-7 (dotted bars), soluble BMP-7 (cross-hatched bars), PEG30k-BMP-7 (dotted bars).
  • Fig. 12A alpha-smooth muscle actin
  • Fig. 12B collagen alpha1(l)
  • BMP-7 refers to bone morphogenetic protein-7. Amino acid sequences of BMP-7 for a variety of species are known, including but not limited to, Homo sapiens (GenBank Accession No. AAG43508; NP_001710), Gallus gallus
  • BMP-7 refers to an amino acid sequence of a BMP-7 from any species, and to fragments and variations of these proteins that retain the desired therapeutic activity of the mature protein.
  • Those of skill in the art recognize that certain portions of a protein are required for therapeutic activity, permitting omission of selected amino acid residues and/or substitution of selected amino acid residues.
  • individual amino acid residues in the protein may be modified by oxidation, reduction, or other derivatization, and the protein may be cleaved to obtain fragments which retain activity. Such alterations which do not destroy biological activity do not remove the protein sequence from the definition.
  • BMP-7 intends any protein sequence that has at least about 70%, more preferably 75%, still more preferably 80%, still more preferably 85%, still more preferably 90%, and still more preferably 95% sequence identity to at least one of the GenBank sequences noted above or to other sequences noted below.
  • Sequence "identity" is determined by comparing the amino acid sequences of polypeptides when aligned so as to maximize overlap and identity while minimizing sequence gaps. The percent identity of two amino acid or two nucleic acid sequences can be determined by visual inspection and/or mathematical calculation, or more preferably, the comparison is done by comparing sequence information using a computer program.
  • An exemplary, preferred computer program is the Genetics Computer Group (GCG; Madison, Wis.) Wisconsin package version 10.0 program, ' GAP ' (Devereux et al., Nucl. Acids Res., 12: 387 (1984)).
  • GCG Genetics Computer Group
  • ' GAP ' Disevereux et al., Nucl. Acids Res., 12: 387 (1984)
  • Other programs used by those skilled in the art of sequence comparison can also be used, such as, for example, the BLAST (BLASTP) and BLASTN programs, available for use via the National Library of Medicine website http://www.ncbi.nlm.nih.gov/BLAST.
  • sequences are considered homologous or identical to one another if their amino acid sequences are at least about 60% identical, more preferably at least 70% identical, still more preferably at least 80% identical, when determined from a visual inspection or from one of the aforementioned computer programs.
  • Hydrophilic polymer refers to a polymer having moieties soluble in water, which lend to the polymer some degree of water solubility at room temperature.
  • exemplary hydrophilic polymers include polyvinylpyrrolidone, polyvinylmethylether, polymethyloxazoline, polyethyloxazoline, polyhydroxypropylyoxazoline, polyhydroxypropyl-methacrylamide, polymethacrylamide, polydimethyl-acrylamide, polyhydroxypropylmethacrylate, polyhydroxyethylacrylate, hydroxymethylcellulose, hydroxyethylcellulose, polyethyleneglycol, polyaspartamide, copolymers of the above-recited polymers, and polyethyleneoxide-polypropylene oxide copolymers. Properties and reactions with many of these polymers are described in U.S. Patent Nos. 5,395,619 and 5,631 ,018.
  • PEGylation refers to the attachment of one or more polyethylene glycol (PEG) substituents or derivatives to a bone morphogenetic protein, such as BMP-7.
  • PEG polyethylene glycol
  • the term refers to covalent attachment of one or more PEG substituents or derivatives by a bond that is not reversible or labile under physiological conditions.
  • a “covalently” attached polymer refers to a linkage that is not generally considered to be reversible or labile under physiological conditions.
  • BMP-7 is human BMP-7, which can be recombinantly produced in Chinese hamster ovary (CHO) cells.
  • human BMP-7 induces bone formation in vivo and increases cell proliferation and collagen synthesis of osteoblasts in vitro (Sampath T.K. etal., J. Biol. Chem., 267(28):20352 (1992)).
  • Recombinant human BMP-7 consists of a 34-38 kDa disulfide linked homodimers identified herein as SEQ ID NO:1.
  • the homodimers migrate as 23, 19, or 27 kDa monomers containing amino acid residues 293-431 of SEQ ID NO:1 , where the amino terminal Met residue of the pre-pro BMP-7 is defined as residue 1 (Ozkaynak, E., EMBO J., 9:2085 (1990)).
  • Residues 29-292 (SEQ ID NO:2) are termed the pro-domain (Jones, W.K. etal., Growth Factors, 1_1.:215 (1994)).
  • the purified BMP-7 homodimers are sparingly soluble in physiological buffers, such as phosphate buffered saline or cell culture media, and require denaturants to remain in solution.
  • physiological buffers such as phosphate buffered saline or cell culture media.
  • the mature domain of recombinant BMP-7 corresponds to residues 293-431 of SEQ ID NO:1 and is referred to herein as "mature" BMP-7 and is identified herein as SEQ ID NO:3.
  • human BMP-7 having a sequence identified herein as SEQ ID NO:3 is used in the composition.
  • the composition includes a human BMP-7 having at least about 70% sequence identity to SEQ ID NO:3, where sequence identity is determined as described above.
  • the composition includes a human BMP-7 having at least 80%, preferably 85%, more preferably 90%, still more preferably 95% sequence identity to the protein sequence identified as SEQ ID NO:3.
  • BMP-7 is chemically modified with one or more hydrophilic polymer chains.
  • Chemical attachment, or conjugation, of hydrophilic polymers to proteins is exemplified in the art with the hydrophilic polymer poly(ethylene glycol) (PEG), however it will be appreciated that other hydrophilic polymers, such as those listed above, are equally suitable.
  • Conjugation of a PEG chain to a protein, such as BMP- 7, is typically one using an "activated derivative" of PEG, i.e, a PEG having a functional group at one or more terminal ends for reaction with, for example an amino group on the protein.
  • Example 1 human mature BMP-7 (SEQ ID NO:3) was mixed with nitrophenyl carbonate derivatized methoxy-PEG (mPEG-NPC) in the presence of an activating agent, exemplified by N-hydroxysuccinimide (HOSu).
  • an activating agent exemplified by N-hydroxysuccinimide (HOSu).
  • Fig. 1 which shows an amine-directed PEGylation of BMP-7
  • reaction of BMP-7 with the acylating agent mPEG-NPC at a neutral pH in the range of 6-7.5 is proceeds slowly.
  • PEGylation of proteins with PEG-NPC proceeds more quickly at a pH greater than 7.5, as PEG-NPC is more reactive under basic conditions.
  • BMP-7 is sparingly soluble in water at neutral and basic pH, making it difficult to chemically modify the protein with efficiency using mPEG-NPC.
  • a conjugate of BMP-7 chemically modified with PEG is prepared by reacting BMP-7 with an acylating agent, like mPEG-NPC, in the presence of an activating agent, as also illustrated in Fig. 1. Addition of the activating agent to the reaction mixture increases the reaction efficiency and allows facile protein modification at neutral pH values (e.g. between 6-7.5) and at pH values below 7.0.
  • the activating agent in Fig. 1 and in Example 1 is exemplified by HOSu.
  • any water-soluble, non-carboxylic, Br ⁇ nstead acid of moderate acidity having the propensity to donate N- or O- linked protons to the PEGylation reagent is suitable for use as the activating agent.
  • General examples include acidic alcohols, phenols, imidazole, triazols and tetrazols, among others.
  • acidic acids suitable for use include, but are not limited to, N- hydroxydicarboxyimides, N-hydroxyphthalimides particularly with nitro and other electron withdrawing substituents on the aromatic ring, N-hydroxy tetrahydrophthalimide, N-hydroxyglutarimide, N-hydroxy-5-norbornene-2,3- dicarboxyimide, and N-hydroxy ⁇ -oxabicyclo ⁇ ijhept- ⁇ -ene ⁇ .S-dicarboxyimide.
  • 1-N-hydroxybenzotriazol and derivatives with electron withdrawing groups on the aromatic ring e.g. nitro, chloro, 3-hydroxy-1 ,2,3-benzotriazin-4(3H)-one.
  • N- hydroxysulfosuccinimide sodium salt is very soluble in water, which means that it can be used at even higher concentration in aqueous buffers than HOSu.
  • exemplary hydroxy amines include, in addition to HOSu, sulfonate derivatives of HOSu, 1-hydroxybenzotriazole (HOBt), and hydroxyl-7-azabenzotriazole (HOAt).
  • the activating agent may be added to a buffer, or may comprise the buffer with or without other salts.
  • HOSu is very soluble in an aqueous solution, it can be added to buffers at relatively high concentration to further boost the PEGylation reaction.
  • phenols such as dinitrophenol, trinitrophenol, trifluorophenol, pentafluorophenol, and pentachlorophenol
  • a PEG-modified BMP-7 was prepared by reacting the mature protein with a functionalized PEG, mPEG-NPC, (mPEG molecular weight of 30 kD), in the presence of HOSu as the activating agent.
  • the resulting PEG-BMP- 7 conjugate referred to herein as mPEG30kDa-BMP-7, was characterized by HPLC size exclusion chromatography prior to purification. As seen in Fig. 2A, about 58% of the BMP-7 was PEGylated, with formation of mono- and di-PEGylated-BMP-7 being favored. Mature BMP-7, which elutes at about 35 minutes (Fig. 2B), was 42% of the total peak area.
  • the PEG30k-BMP-7 composition was comprised of 1 :1 PEG-BMP-7 conjugates (38%), 2:1 PEG-BMP-7 conjugates (16%), and 3:1 PEG-BMP-7 conjugates (4%).
  • Figs. 4A-4B are photographs of the electrophoresis gels stained with
  • Lane 1 is mature BMP-7
  • Lane 2 is the purified preparation of PEG30k-BMP7
  • Lane 3 is the PEG30k-BMP7 1 :1 conjugate.
  • Lane 4 is a molecular weight (MW) marker for proteins in panel A and a molecular weight marker for PEG in panel B.
  • Lanes 5, 6, and 7 correspond to the proteins of Lanes 1 , 2, and 3, respectively, after reduction with mercaptoethanol.
  • the gels confirm the results from the HPLC-SEC, showing that formation of the 1 :1 PEG- protein conjugate was favored.
  • BMP-7 was prepared using a carbohydrate-directed coupling reaction, as described in Example 2 and illustrated in Fig. 5.
  • BMP-7 was oxidized with sodium periodate and then reacted with mPEG-hydrazide (mPEG-Hz), the PEG having a molecular weight of 20 kDa.
  • mPEG-Hz mPEG-hydrazide
  • the resulting composition prior to purification was characterized using HPLC-SEC, as shown in Figs. 6A-6C.
  • the trace for mature BMP-7 is shown in Fig. 6C, the protein elutes at about 36 minutes.
  • the oxidized protein is shown in Fig. 6B, and elutes at about 35 minutes.
  • the PEG20k-Hz-BMP-7 composition was purified by dialysis and ion exchange chromatography and analyzed again by HPLC-SEC. The trace of the composition after purification is shown in Fig. 7.
  • the purified preparation contained 95% of PEGylated BMP-7 and approximately 5% of free protein, with the PEGylated protein fractions as indicated in the figure.
  • the PEG-modified BMP-7 exhibited improved water solubility properties compared to the mature protein.
  • Mature BMP-7 is water soluble at acidic pH (pH ⁇ 5.0), however upon neutralization the protein precipitates.
  • PEG-BMP-7 remains soluble in water above pH 7 and does not precipitate upon neutralization with common buffer salts.
  • the modified BMP-7, PEG30kDa-BMP-7 was tested in vitro to determine if the conjugate retains biological activity. As described in Example 3, the ability of the conjugate to induce alkaline phosphatase specific activity in rat osteoblastic (ROS) cells was evaluated. ROS cells were incubated with various concentrations of mature BMP-7 and PEG30kDa-BMP-7 for 40-56 hours. Induction of alkaline phosphatase was assessed by lysing the cells and analyzing for the presence of alkaline phosphatase via absorbance. The results are shown in Fig. 8. Fig. 8 shows the absorbance (O. D.
  • Biological activity of the PEG-modified BMP-7 conjugate was also tested in vitro using a human kidney (HK-2) cell line. Mature (unpegylated) BMP-7 inhibits production of the cytokines interleukin-6 (IL-6) and interleukin-8 (IL-8).
  • Figs. 9A-9C show that the PEG-BMP-7 conjugates retain biological activity, as evidenced by the ability to inhibit IL-6 production.
  • Fig. 9A shows that the conjugated proteins inhibit IL-6 production over a protein concentration range of 50 ng/mL to 1.75 ng/mL, with the mature, mature BMP-7 (control, squares) and PEG30k-BMP-7 (triangles) having essentially the same inhibitory activity.
  • Figs. 9B and 9C are similar plots over a wider protein concentration range and show that the PEG30k-BMP-7 conjugate retains activity nearly identical to that of the mature, mature protein, with the PEG-20k-Hz-BMP-7 conjugate have a somewhat diminished activity at higher protein concentrations.
  • Figs. 10A-10C show the results for interleukin-8 (IL-8), where mature BMP- 7 (squares) and the PEG-BMP-7 conjugates (triangles) inhibit production of IL-8 at low concentrations (Fig. 10A).
  • Figs. 1OB, 10C At higher concentrations of protein (Figs. 1OB, 10C), the PEG-20k-Hz-BMP-7 conjugate have a somewhat diminished activity (inverted triangles) relative to mature BMP-7, yet still exhibited an ability to inhibit IL-8 production.
  • the PEG30k-BMP-7 conjugate (triangles) retained IL-8 inhibitory activity essentially equivalent to the mature protein.
  • Example 5-7 a problem associated with systemic administration of mature BMP-7 for the treatment of renal failure and osteodystrophy is bone formation at the site of injection.
  • the studies described in Example 6 and 7 provide further confirmation of the results observed in the study of Example 5. Pegylation of BMP-7 prevented injection site ossification in the muscle and skin, indicating that the conjugate is less osteogenic, or more soluble, and capable of rapid dispersion after injection.
  • the results of the studies described in Examples 5 and 6 are summarized in Table 1.
  • the pharmacokinetics of PEGylated-BMP-7 were evaluated by injecting the protein intravenously into rats, as described in Example 8.
  • the blood circulation lifetimes of the conjugate and of mature BMP-7 are shown in Fig. 11.
  • the increased blood circulation lifetime of the PEG30k-BMP-7 conjugate (inverted triangles) relative to mature BMP-7 (triangles) is apparent.
  • treatment methods comprising administering a conjugate comprised of BMP-7 covalently attached to a hydrophilic polymer, such as poly(ethylene glycol) are provided.
  • BMP-7 has a beneficial effect on renal structure and function in patients suffering from acute or chronic renal injury.
  • Administration of BMP-7 in the form of a PEGylated conjugate can increase glomerular filtration rate and renal blood flow, with a decrease in serum creatinine and blood urea nitrogen.
  • BMP-7 also has a beneficial effect in preserving the integrity of vascular smooth muscle cells and in maintaining actin expression in alpha-smooth cells.
  • the conjugate finds particular use in the prevention and treatment of renal conditions, exemplified by but not limited to, renal fibrosis, renal ischemic and/or reperfusion injury, and other conditions evident to those of skill in the art.
  • renal conditions exemplified by but not limited to, renal fibrosis, renal ischemic and/or reperfusion injury, and other conditions evident to those of skill in the art.
  • An exemplary treatment using the PEGylated BMP-7 conjugate is illustrated in
  • Example 9 In this study, a mouse unilateral ureteral obstruction (UUO) model was used to evaluate efficacy of the PEGylated PMB-7 conjugate.
  • the ureters of mice were ligated to block ureteral flow.
  • the ability of PEG30k-BMP-7 to suppress progression of renal fibrosis during a four day period of ureteral obstruction was evaluated.
  • RT- PCR real time reverse transcriptase polymerase chain reaction
  • the level of expression in vehicle treated animals was set to one unit for convenient comparison. The results are shown in Fig. 12A.
  • the relative level of ⁇ -smooth muscle actin in the four day obstructed kidney was reduced in three out of four mice treated with mature BMP-7, in two out of four mice treated with soluble BMP-7, and in two out of three mice treated with PEG BMP-7.
  • the relative level of collagen ⁇ 1(l) expression in the animals was also determined. The results are shown in Fig. 12B.
  • the level of expression in vehicle treated animals was set to one unit.
  • the relative level of collagen ⁇ 1(l) in the four day obstructed kidney was reduced in three out of four mice treated with mature BMP-7, in three out of four mice treated with soluble BMP-7, and in two out of three mice treated with PEG BMP-7.
  • the conjugate composition described above can be formulated for parenteral delivery according to methods well known in the art.
  • the protein is formulated with a suitable carrier vehicle, such as saline or other vehicle that is pharmaceutically-approved.
  • PEG-BMP-7 conjugate can be administered in combination with other therapeutic agents.
  • a specific example includes co- treatment of PEG-BMP-7 with enalapril.
  • BMP-7 human bone morphogenetic protein-7
  • HOSu human bone morphogenetic protein-7
  • Nitrophenyl carbonate derivatized methoxy-polyethylene glycol, molecular weight of 30,000 Daltons was purchased from NOF Corporation (Tokyo, Japan).
  • a 10 mM stock solution of mPEG30k-NPC was prepared in acetonitrile.
  • the reaction (Fig. 1) was initiated by mixing 12.86 ml_ of BMP-7 (18 mg) to 4.24 ml_ of HOSu buffer, pH 6. Afterward, 0.9 mL of mPEG30k-NPC were added drop by drop to the mixture, while gently vortexing. The reaction was allowed to proceed for 16 hours at room temperature (21-22 0 C) on a rocking mixer.
  • the final reaction volume was 18 mL containing 1 mg/mL (0.028 mM) of BMP-7, 0.5 imM of mPEG30k-NPC, 5 % acetonitrile, and a molar ratio of 18 PEG / BMP-7.
  • the final HOSu concentration was 24 mM, which is approximately 48 molar excess over mPEG30k-NPC.
  • the reaction was quenched with 10 mM glycine for 1 hour at room temperature.
  • the product from the conjugation reaction was analyzed by HPLC-SEC using
  • the conjugation reaction sample was dialyzed in 10 mM sodium acetate buffer pH 5, using SPECTRA/POR 1 membrane tubing (Spectrum Medical Industries Inc., Los Angeles, CA), having a molecular weight cut-off of 6000 - 8000.
  • the dialysis was carried out at 4 0 C.
  • the sample was filtered through a 0.45 ⁇ m Acrodisc HT Tuffryn membrane syringe filter (PALL Life Sciences, Ann Arbor, Ml).
  • a sulphopropyl cation exchanger column Source 15S PE 4.6 x 100 mm (GE Healthcare, Piscataway, NJ), 1.7 mL total volume, was equilibrated with 20 column volumes of 10 mM sodium acetate pH 5 buffer.
  • 20 mL of the dialyzed conjugation sample were loaded on the column. Elution was performed by gradient elution using mobile phase A containing 10 mM sodium acetate pH 5, mobile phase B1 containing 1 M NaCI in 10 mM Na Acetate pH 5, and mobile phase B2 containing 6 M Urea, 1 M NaCI, 10 mM Na Acetate pH 5, at a flow rate of 1 ml/min.
  • the unbound material to the column was washed out with 40 mL of mobile phase A.
  • the gradient elution started by increasing mobile phase B1 from 10 % to 60 % in 50 minutes, then to 100 % B2 (1 M NaCI, 6 M Urea) for 10 minutes at 2 mL/min.
  • Fractions from the ion exchange separation containing the PEGylated protein were pooled, concentrated, and dialyzed in 20 mM sodium acetate, 5% mannitol, pH 4.5 buffer, under nitrogen at 20 psi, in a 10 mL Amicon ultrafiltration stirred cell (Millipore Corp., Billerica, MA), using an OMEGA ultrafiltration membrane disc filter (PALL Life Sciences, Ann Arbor, Ml), having a molecular weight cut-off of 3000. The sample volume was brought down to approximately 3.5 mL final volume.
  • the concentrated sample was sterile filtered through 0.22 ⁇ m Acrodisc HT Tuffryn membrane syringe filter, and sterilely filled into autoclaved glass vials. All vials were stored at 4 0 C. Approximately a total of 1.2 mg of PEG30k-BMP-7 was obtained from the purification, as determined by a protein assay described below.
  • B. Protein Determination Assay The protein determination assay was based on the fluorescent characteristic of the protein's intrinsic tryptophan. BMP-7 was used as a standard, and serial dilutions were made at 6.25, 12.5, 25, 50, 100, and 200 ⁇ g/mL in 20 mM sodium acetate, 5% mannitol, pH 4.5 buffer. The mPEG30k-BMP-7 sample was diluted 1:10 and 1 :20 in the same buffer. The standards and test samples were transferred to a black microtiter plate, at 200 ⁇ L/well, in triplicates. The plate was read in a fluorometer set at an excitation wavelength of 295 nm (2 nm slit), and emission wavelength of 360 nm (10 nm slit). The results are shown in Table A.
  • the purified mPEG30k-BMP7 sample was analyzed by size exclusion chromatography using Superose6 10/300 GL column described above.
  • the sample was diluted to 50 ⁇ g/mL in the mobile phase, and 50 ⁇ L were injected to the column.
  • the flow rate was set to 0.5 mL/min, and elution off the column was monitored by a fluorescence detector set at an excitation wavelength of 295 nm, and emission wavelength of 360 nm (bandwidth 15 nm).
  • the results are shown in Fig. 3 for the mature protein and for the conjugate.
  • the mPEG30k-BMP7 sample was analyzed by gel electrophoresis under denaturing conditions, using NuPAGE ® Bis-Tris 4 - 12 % gradient gel and MOPS- SDS running buffer (Invitrogen Life Technology, Carlsbad, CA). Samples and controls were loaded on 2 gels at 10 ⁇ L/well containing 1.5 to 5 ⁇ g of protein. The gels were run at a constant voltage of 200 volts for 55 minutes. One gel was stained in Coomassie Blue for protein detection and the other in iodine for PEG detection, as shown in Figs. 4A-4B, respectively.
  • FIG. 5 This reaction scheme is shown in Fig. 5.
  • A. Conjugation Reaction A two step reaction of oxidation and conjugation was performed using recombinant human BMP-7. A 2.8 mg/mL BMP7 stock solution was prepared in 25 mM sodium acetate pH 5 buffer (15.6 mg total BMP-7). The BMP-7 oxidation reaction was carried out in 1 mM sodium periodate for 20 minutes at 4 0 C, then quenched with 2 mM ⁇ /-acetyl-methionine. Then, a 5 mM stock solution of methoxy-polyethylene glycol 20000-hydrazide
  • mPEG20k-Hz was prepared in 25 mM sodium acetate buffer pH 5.
  • the oxidized BMP-7 14 mg was reacted with the mPEG20k-Hz at 1.4 mg/mL of BMP-7 (0.039 mM) and 2.9 mM mPEG20k-Hz, resulting in a molar ratio of 75 /1 PEG per protein, for 16 hours at room temperature (21 - 22 0 C) on a rocking mixer.
  • the product of the conjugation reaction was analyzed by HPLC-SEC using Superose ⁇ 10/300 GL, 1 x 30 cm column (GE Healthcare, Piscataway, NJ), and 25 mM Tris, 300 mM NaCI, 6 M Urea, pH 6.5, mobile phase.
  • the sample was diluted 1/20 in the mobile phase, and 50 ⁇ L were injected to the column.
  • the flow rate was set at 0.5 ml/min, and elution off the column was monitored by a fluorescence detector set at an excitation wavelength of 295 nm, and emission wavelength of 360 nm (bandwidth 15 nm).
  • the HPLC-SEC traces for the mPEG20k-Hz-BMP-7 conjugate, the oxidized BMP-7, and mature BMP-7 are shown in Figs. 6A-6C, respectively.
  • the conjugate was dialyzed in 5 mM sodium phosphate buffer pH 7, using SPECTRA/POR 1 membrane tubing (Spectrum Medical Industries Inc., Los Angeles, CA), having a molecular weight cut-off of 6000 - 8000.
  • the dialysis was carried out at 4 °C.
  • the sample was filtered through a 0.45 ⁇ m Acrodisc HT Tuffryn membrane syringe filter (PALL Life Sciences, Ann Arbor, Ml).
  • mobile phase A containing 5 mM sodium phosphate buffer pH 7
  • mobile phase B1 containing 1 M NaCI in 20 mM sodium phosphate pH 7
  • mobile phase B2 containing 6 M Urea, 1 M NaCI, 20 mM sodium phosphate pH 7.
  • the elution started by increasing mobile phase B1 to 30 % for 30 minutes at 2 ml_/min, then to 100 % B2 for 4 minutes at 4 mL/min. Fractions were collected at 5 mL/fraction throughout the entire separation. Unreacted PEG did not bind to the column, and came out with the flow-through fractions. However, PEGylated-BMP7 and unconjugated BMP7 were both eluted at 30% of mobile phase B1 (30 mM NaCI).
  • the fractions containing PEGylated-BMP7 and unconjugated BMP7 from the ion exchange chromatography separation were pooled and subjected to further purification by hydrophobic interaction chromatography in order to separate the PEGylated-BMP7 from the unconjugated BMP7.
  • the flow through peak was collected in 5 mL fractions and reinjected in order to obtain maximum binding to the column.
  • the gradient was then changed to 70% A and 30% B (6 M urea, 20 mM Na phosphate pH 7), and increased to 100% B over 70 minutes, followed by 20 minutes at 100% B.
  • Fractions were collected at 1 mL/fraction throughout the elution stage.
  • aliquots from the fractions were analyzed by HPLC-SEC using Superose ⁇ 10/300 GL column described above.
  • Fractions from the hydrophobic interaction separation containing the PEGylated protein were pooled concentrated and dialyzed in PBS pH 7.2, under nitrogen at 20 psi, in a 10 mL Amicon ultrafiltration stirred cell (Millipore Corp., Billerica, MA), using an OMEGA ultrafiltration membrane disc filter (PALL Life Sciences, Ann Arbor, Ml), having a molecular weight cut-off of 3000.
  • the sample volume was brought down to 4 mL final volume.
  • the concentrated sample was sterile filtered through 0.22 ⁇ m Acrodisc HT
  • the purified mPEG20k-Hz-BMP7 sample was analyzed by size exclusion chromatography using the Superose ⁇ 10/300 GL column described above.
  • the sample was diluted to 1/10 in the mobile phase, and 50 ⁇ L were injected to the column.
  • the flow rate was set to 0.5 mL/min, and elution off the column was monitored by a fluorescence detector set at an excitation wavelength of 295 nm, and emission wavelength of 360 nm (bandwidth 15 nm). Results are shown in Fig.
  • the quantitation of activity is based on the induction of alkaline phosphatase specific activity in rat osteoblastic (ROS) cells.
  • ROS rat osteoblastic
  • 30,000 cells/well (in 200 ⁇ l_) were added to flat bottom plate and incubated overnight at 37 0 C.
  • BMP-7 was diluted in acetate/mannitol buffer pH 4.5 to a concentration of 0.5 mg/mL.
  • a 4 ⁇ g/mL working stock solutions of both PEG30k-BMP-7 (prepared as described in Example 1) and mature BMP-7 were made in acetate/mannitol buffer.
  • Serial dilutions of both were made in F12 media with 2 mg/mL BSA.
  • 50 ⁇ L of samples of the conjugate or the mature protein were added to the plate in triplicate.
  • the final concentrations of the samples are as follows: 800, 400, 200, 100, 50, 25, 12.5, 6.25, 3.125 and 0 ng/mL
  • the plate was incuba
  • condition media 150 uL was removed and discarded.
  • 100 ⁇ L of a warmed 2% Triton-X 100 solution was added to each well. The plate was placed back into the incubator for 60 minutes to lyse the cells and release the alkaline phosphatase molecules. The plate was incubated at 4 0 C overnight to assure completion of the extraction process.
  • PNPP p-nitrophenylphosphate
  • HK-2 cell line Human kidney (HK-2 cell line) cells were cultured in keratinocyte serum free medium supplemented with 5 ng/mL recombinant human epidermal growth factor
  • rHuEGF rHuEGF
  • bovine pituitary extract complete K-SFM
  • Cells were rinsed with K-SFM without supplements and then treated for 6 hours with K-SFM (no supplements) alone or with the addition of 100 ng/mL BMP-7, 2 ng/mL TNF- ⁇ , or 100 ng/mL BMP-7 and 2 ng/mL TNF- ⁇ .
  • RNA was isolated using Qiagen RNAeasy kit and RT-PCR was performed. IL-6 levels were attenuated in the presence of BMP-7.
  • the cells were cultured in complete K-SFM at 100,000 cells per well in a 24 well plate overnight. Medium was removed and replaced with K-SFM without supplements containing BMP-7 (0, 25, 50, 100, 200, 400 ng/mL), TGF- ⁇ 1 (0, 0.31 , 0.625, 1.25, 2.5 or 5 ng/ml) or TNF- ⁇ (2 ng/mL) plus BMP-7 or TGF ⁇ i for 24 hours. Supematants were collected asceptically into sterile microfuge tubes, spun at 2000 rpm in a microcentrifuge to remove cell debris, and transferred to fresh tubes. Supematants were stored frozen (-2O 0 C) until analysis by ELISA. IL-6 and IL-8 were quantitated by ELISA detection (R&D Systems) per manufacturers directions.
  • Mature BMP-7 was obtained and PEGylated BMP-7 conjugate was prepared as described in Example 1 , with PEG molecular weight of 30,000 Daltons. Twenty male rats were obtained and randomized into four groups for treatment. Each animal acted as its own control by delivering the mature protein or the PEGylated protein to the left flank and the control vehicle to the right flank.
  • the treatment groups were as follows:
  • Injections of the protein at a dose of 100 ⁇ g/kg and in a mannitol acetate buffer carrier vehicle were given in the left flank.
  • the right flank of each animal was injected with the mannitol acetate buffer vehicle by the same delivery route as the protein given to the right flank.
  • a single injection was given and the animals were observed for two weeks post injection. No signs of obvious or palpable nodules formed at the injection site during this two week observation period.
  • Tissue samples were removed from the animals and placed into 5% PVA. They were frozen using a hexane freezing bath and placed into -80°C freezer. The majority of these blocks were subsequently thawed in 70% alcohol and processed for microCT analysis. Bone was observed in 4/5 muscles in the animals receiving i.ni. BMP-7 (Group 3) and 5/5 in the animals receiving s.c. BMP- 7 (Group 1 ). The results are summarized in Table B.
  • Ten male rats were obtained and randomized into two groups for treatment. Each animal acted as its own control by delivering the mature protein or the PEGylated protein to the left flank and the control vehicle to the right flank.
  • the treatment groups were as follows:
  • Injections of the protein at a dose of 100 ⁇ g/kg and in a mannitol acetate buffer carrier vehicle were given in the left flank intramuscularly.
  • the right flank of each animal was injected with the mannitol acetate buffer vehicle by the same delivery route as the protein given to the right flank.
  • the rats were anesthetized with a 70/30 mixture of CO 2 /O 2 . Care was taken to ensure that animal's bone was not hit by the needle or that bone was not too close to the injection site.
  • a single injection was given and the animals were euthanized two weeks post injection for analysis. X-ray analysis of the injection area showed bone nodules in all of the animals treated with mature BMP-7.
  • Each animal acted as its own control by delivering the mature protein or the PEGylated protein to the left flank and the control vehicle to the right flank.
  • the treatment groups were as follows:
  • Injections of the protein at a dose of 100 ⁇ g/kg and in a mannitol acetate buffer carrier vehicle were given in the left flank intramuscularly.
  • the right flank of each animal was injected with the mannitol acetate buffer vehicle by the same delivery route as the protein given to the right flank.
  • a single injection was given and the animals were euthanized two weeks post injection for analysis.
  • a standard was prepared by diluting a BMP-7 reference standard in 50 mM Tris-buffered saline (TBS) + 1 % bovine serum albumin (BSA) to a concentration of 10 ⁇ g/mL. The standard was aliquoted and stored at-80 0 C.
  • a first dilution of 800 ng/mL of the 10 ⁇ g/mL reference standard in serum, plasma, or assay detergent diluent/sample buffer (5OmM TRIS, 15OmM NaCI, 0.1 % SDS, 1% NP-40, 0.5% DOC pH 8.0) was prepared.
  • a standard curve was determined by performing a series of 1 :2 dilutions in serum, plasma, or assay detergent diluent/sample buffer.
  • the standard concentrations (final) were: 800, 400, 200, 100, 50, 25, 12.5, 6.25, 3.125, 1.56, 0.78, 0.39, 0.195, 0.097, 0.048, and 0 ng/mL 50 ⁇ L of the standard controls and of the test samples were added to the appropriate wells. 50 ⁇ L of assay detergent diluent/sample buffer was added to all wells.
  • the plate was securely covered with a plate sealer and incubated for 2 hours at room temperature (20-25 0 C) on a shaker (speed 4).
  • BMP-7 wash buffer (1x borate buffered saline, 0.1 % Tween 20, pH 8.0) for 2 cycles and the plates were tapped dry.
  • a Creative BioMolecules Rabbit 5086 (BMP-7 polyclonal antibody) was diluted 1 :2500 in BMP-7 conjugate diluent (5OmM TRIS, 15OmM NaCI, 1 % BSA, pH 7.2) and 50 ⁇ L was added to all the wells.
  • the plates were covered securely with a plate sealer and incubated for 1 hour at room temperature (20-25 0 C) on a shaker. Then, the plates were washed on the plate washer, 2 cycles as described above.
  • a unilateral ureteral obstruction (UUO) model was used to evaluate efficacy of the PEGylated PMB-7 conjugate.
  • the ureter of mice was ligated to block ureteral flow.
  • the ability of mature BMP-7 (SEQ ID NO:3), soluble BMP-7 (residues 30-431 of SEQ ID NO:1 ; mature domain with the amino terminal prodomain of the protein non-covalently in association with the mature BMP-7), and the PEG30k ⁇ BMP-7 conjugate (prepared as described above) to suppress the expression of markers of renal fibrosis, as a measure of ability to suppress progression of renal fibrosis was determined during a four day period of ureteral obstruction.
  • the levels of beta actin, alpha smooth muscle, and collagen were determined from kidney tissue samples taken from each animal at the end of the four day period, using real time RT-PCR. The beta actin was measured by spiking a beta actin cDNA as a control. The level of expression in vehicle treated animals was set to one unit for convenient comparison. Results are shown in Figs. 12A-12B.
  • mice Male Balb/C mice are injected with PEG30k-BMP-7 or with mature BMP-7. Fourteen days later, the mice receive a second injection of the same test compound. Blood samples are drawn weekly from Day 0 to Day 35, serum is separated and the presence of anti-PEG-BMP-7 antibodies are detected using ELISA.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne une composition protéique morphogénétique osseuse modifiée (BMP, également dite protéine morphogénétique osseuse). Il s'agit, dans un mode de réalisation, de la protéine morphogénétique osseuse BMP-7 qui est modifiée chimiquement à l'aide d'un polymère hydrophile, tel que le poly(éthylène glycol).
PCT/US2006/021215 2005-06-01 2006-05-31 Conjugues macromoleculaires de la proteine morphogenetique osseuse 7 WO2006130745A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2008514832A JP2008542388A (ja) 2005-06-01 2006-05-31 骨形態形成蛋白質−７の高分子共役体
EP06760616A EP1893238A1 (fr) 2005-06-01 2006-05-31 Conjugues macromoleculaires de la proteine morphogenetique osseuse 7

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68680505P 2005-06-01 2005-06-01
US60/686,805 2005-06-01

Publications (1)

Publication Number Publication Date
WO2006130745A1 true WO2006130745A1 (fr) 2006-12-07

Family

ID=36928595

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/021215 WO2006130745A1 (fr) 2005-06-01 2006-05-31 Conjugues macromoleculaires de la proteine morphogenetique osseuse 7

Country Status (4)

Country Link
EP (1) EP1893238A1 (fr)
JP (1) JP2008542388A (fr)
TW (1) TW200716178A (fr)
WO (1) WO2006130745A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010054440A1 (fr) * 2008-11-14 2010-05-20 Ruchong Ou, Trading As International Program Funds Of Australia Composés bmp-7 destinés à moduler l'expression de la transcriptase inverse de la télomérase
CN102757992A (zh) * 2011-04-25 2012-10-31 中国科学院大连化学物理研究所 一种聚乙二醇偶联结合超滤离心分离富集糖肽的方法
CN104710506A (zh) * 2013-12-13 2015-06-17 中国科学院大连化学物理研究所 一种糖蛋白质富集纯化方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0512844A1 (fr) * 1991-05-10 1992-11-11 Celtrix Pharmaceuticals, Inc. Délivrance ciblée de facteurs de croissance ostéogoniques
US20050079155A1 (en) * 2003-03-20 2005-04-14 Xencor, Inc. Generating protein pro-drugs using reversible PPG linkages
US20050114037A1 (en) * 2003-03-31 2005-05-26 Xencor, Inc. Methods for rational pegylation of proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0512844A1 (fr) * 1991-05-10 1992-11-11 Celtrix Pharmaceuticals, Inc. Délivrance ciblée de facteurs de croissance ostéogoniques
US20050079155A1 (en) * 2003-03-20 2005-04-14 Xencor, Inc. Generating protein pro-drugs using reversible PPG linkages
US20050114037A1 (en) * 2003-03-31 2005-05-26 Xencor, Inc. Methods for rational pegylation of proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SIMIC P ET AL: "Bone morphogenetic proteins in development and homeostasis of kidney", CYTOKINE AND GROWTH FACTOR REVIEWS, OXFORD, GB, vol. 16, no. 3, 31 May 2005 (2005-05-31), pages 299 - 308, XP004964510, ISSN: 1359-6101 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010054440A1 (fr) * 2008-11-14 2010-05-20 Ruchong Ou, Trading As International Program Funds Of Australia Composés bmp-7 destinés à moduler l'expression de la transcriptase inverse de la télomérase
CN102757992A (zh) * 2011-04-25 2012-10-31 中国科学院大连化学物理研究所 一种聚乙二醇偶联结合超滤离心分离富集糖肽的方法
CN102757992B (zh) * 2011-04-25 2014-09-03 中国科学院大连化学物理研究所 一种聚乙二醇偶联结合超滤离心分离富集糖肽的方法
CN104710506A (zh) * 2013-12-13 2015-06-17 中国科学院大连化学物理研究所 一种糖蛋白质富集纯化方法

Also Published As

Publication number Publication date
EP1893238A1 (fr) 2008-03-05
JP2008542388A (ja) 2008-11-27
TW200716178A (en) 2007-05-01

Similar Documents

Publication Publication Date Title
US20190023743A1 (en) Methods and compositions for modulating drug-polymer architecture, pharmacokinetics and biodistribution
Bidwell III et al. A kidney-selective biopolymer for targeted drug delivery
JP7296958B2 (ja) 手術前、手術中または手術後に投与するためのｇｌｐ－２類似体及びｇｌｐ－２ペプチボディ
JPH07500315A (ja) 骨成長因子の標的送達
JP2011526626A5 (fr)
KR20090071598A (ko) 수용체 결합 단백질(ｒａｐ)-접합체 투여에 의한 간 질환의 치료
US20120282211A1 (en) Antibodies and conjugates for modulators of angiogenesis
JP2015512369A (ja) Ｃ１阻害剤のポリマーコンジュゲート
Motokawa et al. Selectively crosslinked hyaluronic acid hydrogels for sustained release formulation of erythropoietin
BRPI0613332A2 (pt) isoformes de fator estimulante de colÈnia granulocìtica humana
US20070015701A1 (en) Macromolecular conjugates of bone morphogenetic protein-7
AU2009243343B2 (en) Heparin-conjugated fibrin gel and method and kit for preparing the same
EP3539570B1 (fr) Analogue d'endostatine pegylé et application associée
US11723957B2 (en) Compositions comprising relaxin and methods of use thereof
Liu et al. Synthetic polypeptides inhibit nucleic acid-induced inflammation in autoimmune diseases by disrupting multivalent TLR9 binding to LL37-DNA bundles
EP1893238A1 (fr) Conjugues macromoleculaires de la proteine morphogenetique osseuse 7
EP2460540A1 (fr) Agent d'administration de médicament ciblant le rein, comprenant de la gélatine modifiée génétiquement
US20060286657A1 (en) Novel bioconjugation reactions for acylating polyethylene glycol reagents
Fukushima et al. Glycosaminoglycan-conjugated insulin derivatives suitable for once-daily formulations
JP2018508580A (ja) ペグ化ｉｌ−１１の組成物および方法
McVicar et al. Radiomitigation and tissue repair activity of systemically administered therapeutic peptide TP508 is enhanced by PEGylation
KR102090551B1 (ko) 소수성 단백질의 새로운 방출 시스템
Oss‐Ronen et al. Photopolymerizable Hydrogels Made from Polymer‐Conjugated Albumin for Affinity‐Based Drug Delivery
WO2015021044A1 (fr) Compositions et procédés pour la libération en réponse à des stimuli d'un agent thérapeutique
White et al. Engineered collagen-targeting therapeutics reverse lung and kidney fibrosis in mice

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2008514832

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2006760616

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载